Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Likun Chen

Showing results (11-20 of 123) with videos related to

Pageof 13
Sort By:
Journal of Inflammation Research|March 25, 2024
Prognostic Nutritional Index Predicts Efficacy and Immune-Related Adverse Events of First-Line Chemoimmunotherapy in Patients with Extensive-Stage Small-Cell Lung CancerBaishen Zhang, Jing Chen, Hui Yu, et al.
Medical Oncology (Northwood, London, England)|March 6, 2010
Validation of a clinical prognostic model in Chinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinibFenghua Wang, Yang Zhang, Hongyun Zhao, et al.
Translational Oncology|August 19, 2025
High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective studyYin Pan, Meichen Li, Mingjie Yu, et al.
Chemosphere|September 17, 2019
Highly efficient removal of organic pollutants via a green catalytic oxidation system based on sodium metaborate and peroxymonosulfateLongjun Rao, Yunfei Yang, Likun Chen, et al.
Scientific Reports|January 7, 2017
ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristicsWei Zhang, Zhen Chen, Likun Chen, et al.
Lung Cancer (Amsterdam, Netherlands)|January 29, 2022
ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061)Meichen Li, Xue Hou, Jing Chen, et al.
Cancer Science|August 16, 2025
Comparison of the Efficacy of Different First-Line Therapies for EGFR L858R-Mutated NSCLC Patients With Brain MetastasesJing Chen, Yin Pan, Baishen Zhang, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|April 23, 2013
[The cost-effectiveness analysis of gefitinib or erlotinib in the treatment of advanced EGFR mutant non-small cell lung cancer patients]Yuxiang Ma, Yan Huang, Hongyun Zhao, et al.
Scientific Reports|July 24, 2020
Author Correction: ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristicsWei Zhang, Zhen Chen, Likun Chen, et al.
Angewandte Chemie (International Ed. in English)|March 10, 2023
Determining the Role of Ion Transport Throughput in Solid-State Lithium BatteriesKe Yang, Liang Zhao, Xufei An, et al.
Pageof 13

Showing results (11-20 of 123) with videos related to

Sort By:
Pageof 13
Journal of Inflammation Research|March 25, 2024
Prognostic Nutritional Index Predicts Efficacy and Immune-Related Adverse Events of First-Line Chemoimmunotherapy in Patients with Extensive-Stage Small-Cell Lung CancerBaishen Zhang, Jing Chen, Hui Yu, et al.
Medical Oncology (Northwood, London, England)|March 6, 2010
Validation of a clinical prognostic model in Chinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinibFenghua Wang, Yang Zhang, Hongyun Zhao, et al.
Translational Oncology|August 19, 2025
High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective studyYin Pan, Meichen Li, Mingjie Yu, et al.
Chemosphere|September 17, 2019
Highly efficient removal of organic pollutants via a green catalytic oxidation system based on sodium metaborate and peroxymonosulfateLongjun Rao, Yunfei Yang, Likun Chen, et al.
Scientific Reports|January 7, 2017
ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristicsWei Zhang, Zhen Chen, Likun Chen, et al.
Lung Cancer (Amsterdam, Netherlands)|January 29, 2022
ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061)Meichen Li, Xue Hou, Jing Chen, et al.
Cancer Science|August 16, 2025
Comparison of the Efficacy of Different First-Line Therapies for EGFR L858R-Mutated NSCLC Patients With Brain MetastasesJing Chen, Yin Pan, Baishen Zhang, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|April 23, 2013
[The cost-effectiveness analysis of gefitinib or erlotinib in the treatment of advanced EGFR mutant non-small cell lung cancer patients]Yuxiang Ma, Yan Huang, Hongyun Zhao, et al.
Scientific Reports|July 24, 2020
Author Correction: ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristicsWei Zhang, Zhen Chen, Likun Chen, et al.
Angewandte Chemie (International Ed. in English)|March 10, 2023
Determining the Role of Ion Transport Throughput in Solid-State Lithium BatteriesKe Yang, Liang Zhao, Xufei An, et al.
Pageof 13